aulin 100 mg zrnca za peroralno suspenzijo
angelini pharma Ősterreich gmbh - nimesulid - zrnca za peroralno suspenzijo - nimesulid 100 mg / 1 vrečica - nimesulid
atgam 50 mg/ml koncentrat za raztopino za infundiranje
pfizer luxembourg sarl - imunoglobulin proti limfocitom t, humani - koncentrat za raztopino za infundiranje - imunoglobulin proti limfocitom t, humani 50 mg / 1 ml - imunoglobulin proti limfocitom (konjski)
tysabri
biogen netherlands b.v. - natalizumab - multiple skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
lomexin 20 mg/g vaginalna krema
recordati ireland ltd. - fentikonazolijev nitrat - vaginalna krema - fentikonazolijev nitrat 20 mg / 1 g - fentikonazol
rhokiinsa
santen oy - netarsudil - glaucoma, open-angle; ocular hypertension - oftalmologi - znižanje zvišanega očesnega tlaka (iop) pri odraslih bolnikih z primarni glavkom odprtega zakotja ali očesni hipertenzija.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.